World Health Organization/HIVResNet drug resistance laboratory strategy

Bertognolio, Silvio, Derdelinckx, Inge, Parker, Monica, Fitzgibbon, Joseph, Fleury, Herve, Peeters, Martin, Schuurman, Rob, Pillay, Deenan, Morris, Lynn, Tanuri, Amilcar, Gershy-Damet, Guy-Michel, Nkengasong, John, Gilks, Charles F., Sutherland, Donald and Sandstrom, Paul (2008) World Health Organization/HIVResNet drug resistance laboratory strategy. Antiviral Therapy, 13 Suppl. 2: 49-57.

Author Bertognolio, Silvio
Derdelinckx, Inge
Parker, Monica
Fitzgibbon, Joseph
Fleury, Herve
Peeters, Martin
Schuurman, Rob
Pillay, Deenan
Morris, Lynn
Tanuri, Amilcar
Gershy-Damet, Guy-Michel
Nkengasong, John
Gilks, Charles F.
Sutherland, Donald
Sandstrom, Paul
Title World Health Organization/HIVResNet drug resistance laboratory strategy
Journal name Antiviral Therapy   Check publisher's open access policy
ISSN 1359-6535
2040-2058
Publication date 2008-01
Year available 2008
Sub-type Article (original research)
Volume 13
Issue Suppl. 2
Start page 49
End page 57
Total pages 9
Place of publication London, United Kingdom
Publisher International Medical Press
Collection year 2009
Language eng
Formatted abstract
With rapidly increasing access to antiretroviral drugs globally, HIV drug resistance (HIVDR) has become a significant public health issue. This requires a coordinated and collaborative response from country level to international level to assess the extent of HIVDR and the establishment of efficient and evidence-based strategies to minimize its appearance and onward transmission. In parallel with the rollout of universal access to HIV treatment, countries are developing protocols based on the recommendations of the World Health Organization (WHO) to measure, at a population level, both transmitted HIVDR and HIVDR emerging during treatment. The WHO in collaboration with international experts (HIVResNet Laboratory Working Group), has developed a laboratory strategy, which has the overall goal of delivering quality-assured HIV genotypic results on specimens derived from the HIVDR surveys. The results will be used to help control the emergence and spread of drug resistance and to guide decision makers on antiretroviral therapy policy at national, regional and global level. The HIVDR Laboratory Strategy developed by the WHO includes several key aspects: the formation of a global network of national, regional and specialized laboratories accredited to perform HIVDR testing using a common set of WHO standard and performance indicators; recommendations of acceptable methods for collection, handling, shipment and storage of specimens in field conditions; and the provision of laboratory technical support, capacity building and quality assurance for network laboratories. The WHO/HIVResNet HIVDR Laboratory Network has been developed along the lines of other successful laboratory networks coordinated by the WHO. As of August 2007, assessment for accreditation has been conducted in 30 laboratories, covering the WHO'S African, South-East Asia, Western Pacific, and the Caribbean Regions.
Keyword Immunodeficiency Virus Rna
Dried Blood Spots
Whole Blood
Plasma
Surveillance
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 33 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Fri, 07 Jun 2013, 20:06:02 EST by System User on behalf of School of Public Health